- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 247 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,517 | +2,52 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | ||
| IMMATICS | 8,775 | -2,88 % | Immatics Appoints Amie Krause as Chief People Officer | Houston, Texas and Tuebingen, Germany, October 27, 2025 - Immatics N.V.as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedInand Instagram.Forward-Looking... ► Artikel lesen | |
| ALDEYRA | 4,316 | +0,16 % | Aldeyra reshuffles pipeline, culling asset despite Phase II success | ||
| MEDIFAST | 10,560 | +0,62 % | Medifast richtet sich neu aus: Fokus auf metabolische Gesundheit mit wissenschaftlichem Ansatz | ||
| PHARMING | 1,146 | +2,14 % | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,479 | +0,96 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| ORUKA THERAPEUTICS | 24,000 | -1,64 % | H.C. Wainwright senkt Kursziel für Oruka Therapeutics nach Finanzierung auf 40 US-Dollar | ||
| ARMATA PHARMACEUTICALS | 4,240 | -7,42 % | XFRA TG1N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| INNOVIVA | 15,500 | 0,00 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,265 | -0,30 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results | ||
| DBV TECHNOLOGIES | 2,645 | +4,55 % | DBV Technologies S.A.: DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors | Châtillon, France, October 30, 2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market:... ► Artikel lesen | |
| LIQUIDIA | 19,920 | -0,70 % | What's Next: Liquidia's Earnings Preview | ||
| SYNDAX PHARMACEUTICALS | 12,100 | +4,31 % | XFRA 1T3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSYNDAX PHARMACEU.DL-... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,370 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
MOLECURE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,542 Euro und damit -6,77 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.